Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.

Authors:
Thiago Gagliano-Jucá, MD, PhD
Thiago Gagliano-Jucá, MD, PhD
Brigham and Women's Hospital, Harvard Medical School
Research Fellow
Andrology
Boston, Massachusetts | United States

Am J Physiol Endocrinol Metab 2018 12 16;315(6):E1185-E1193. Epub 2018 Oct 16.

Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts.

Androgen deprivation therapy (ADT) is a mainstay of treatment for prostate cancer (PCa). As androgens stimulate erythropoiesis, ADT is associated with a reduction in hematocrit, which in turn contributes to fatigue and related morbidity. However, the mechanisms involved in ADT-induced reduction in erythropoiesis remain unclear. We conducted a 6-mo prospective cohort study and enrolled men with PCa about to undergo ADT (ADT-Group) and a control group of men who had previously undergone prostatectomy for localized PCa and were in remission (Non-ADT Group). All participants had normal testosterone levels at baseline. Fasting blood samples were collected at baseline, 12 wk, and 24 wk after initiation of ADT; samples were obtained at the same intervals from enrollment in the Non-ADT group. Blood count, iron studies, erythropoietin, erythroferrone, and hepcidin levels were measured. Seventy participants formed the analytical sample (31 ADT, 39 Non-ADT). ADT was associated with a significant reduction in erythrocyte count (estimated mean difference = -0.2×10 cells/µl, 95%CI = -0.3 to -0.1×10 cells/µl, P < 0.001), hematocrit (-1.9%, 95%CI = -2.7 to -1.1%, P < 0.001), and hemoglobin (-0.6 g/dl, 95%CI = -0.8 to -0.3 g/dl, P < 0.001). Serum hepcidin concentration increased in the ADT-group (18 ng/ml, P < 0.001); however, iron concentrations did not change (-1.1 µg/dl, P = 0.837). Ferritin levels increased in men on ADT (60 ng/ml, P < 0.001). Iron binding capacity, transferrin saturation, erythroferrone, and erythropoietin did not change. Nine men undergoing ADT developed new-onset anemia. In conclusion, reduced proliferation of marrow erythroid progenitors leads to ADT-induced reduction in erythropoiesis. Future studies should evaluate the role of selective androgen receptor modulators in the treatment of ADT-induced anemia.

Download full-text PDF

Source
https://www.physiology.org/doi/10.1152/ajpendo.00272.2018
Publisher Site
http://dx.doi.org/10.1152/ajpendo.00272.2018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336960PMC
December 2018
42 Reads
3.785 Impact Factor

Publication Analysis

Top Keywords

adt associated
8
adt
8
prostate cancer
8
associated reduction
8
0001 iron
8
non-adt group
8
reduction erythropoiesis
8
ng/ml 0001
8
deprivation therapy
8
adt-induced reduction
8
androgen deprivation
8
0001
5
men
5
95%ci = -03 -01×10
4
cells/µl 95%ci = -03
4
cells/µl 0001
4
difference = -02×10 cells/µl
4
-01×10 cells/µl
4
count estimated
4
non-adt adt
4

References

(Supplied by CrossRef)

Similar Publications